EyePoint Pharmaceuticals Inc
EYPT
Get informed when a big investor buys or sells
+ FollowMarket Cap$272.48M
Close$
$-1.99
161.1% downside
Current Fair Value
161.1% downsideOvervalued by 161.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $272.48 Million |
|---|---|
| Enterprise Value | $184.39 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.17 |
| Beta | 1.64 |
| Outstanding Shares | 86,543,000 |
Return
| Return on Equity | -184.27% |
|---|---|
| Return on Assets | -134.38% |
| Return on Invested Capital | -168.63% |
Valuation & Multiples
| P/E Ratio | -0.87 |
|---|---|
| PEG | -1.47 |
| Price to Sales | - |
| Price to Book Ratio | 3.25 |
| Enterprise Value to Revenue | 66.11 |
| Enterprise Value to EBIT | -0.59 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-1.01
Average shareholder expectationRevenue Estimate
$443,000
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.91
Average shareholder expectationRevenue Estimate
$231,154
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.8969▲ 154.67% |
|---|---|
| Total Calls | 1,540,169▼ 6.44% |
| Total Puts | 2,921,500▲ 406.85% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 108.01%▲ 4.20% |
|---|---|
| Total Invested | $1.34B▲ 16.30% |
| Investors Holding | 209▲ 5.00% |
ESG Score
No data